Single-cell sequencing firm Parse Biosciences said in a statement that it has raised $50 million through a Series C financing round combined with a debt facility from Horizon Technology Finance.
According to Parse Biosciences, this new funding brings the company’s total funding to over $100 million. The company closed a previous $41.5 million Series B financing round in early 2022.
The firm did not disclose how much of the $50 million came from the financing round and how much came from the debt facility.
The round was led by Soleus Capital, joined by new and current investors including Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital.
The Seattle-based firm said in its statement that it will use the funds to “fuel its expansion, further scale to meet the increasing demand for its technology, and continue to serve its academic, biotech, and pharma customers.”
Parse emerged as a University of Washington spinout in 2021; its single-cell portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and CRISPR Detect, as well as data analysis solutions for use in applications such as immune profiling and pooled CRISPR screens.
